ABT · Earnings call · 2026Q3T · Full report

CRC Screening Market Demand

ABBOTT LABORATORIES · 2026-10-21 · Importance 30 · Surprise 40

Cologuard grew at a mid-teens rate, with growth in new users, rescreening, international markets, and care-gap programs. Management said care-gap program growth is valuable to health systems and insurers because it supports star ratings and Medicare CMS rebates, but order timing depends on when those customers choose to send tests. Management described the Exact business as performing as expected and said it sees further growth opportunities across existing products, segments, and countries.

Key facts

• Cologuard grew at a mid-teens rate and continued to accelerate.
• Abbott said stool-based testing is preferred by medical societies and standard-of-care recommendations because it performs better in early detection than the blood test.
• Abbott said care-gap programs grew, but their timing is difficult to forecast because insurers and health systems determine when orders are sent, sometimes while managing expenses.
• Abbott reported growth in Cologuard new users, rescreening, international business, and care-gap programs.